Kronos Bio Inc.

NASDAQ: KRON · Real-Time Price · USD
0.68
0.01 (1.27%)
At close: May 30, 2025, 3:59 PM
0.66
-2.74%
After-hours: May 30, 2025, 05:48 PM EDT

Company Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics.

The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity.

Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations.

It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial.

The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio Inc.
Kronos Bio Inc. logo
Country United States
IPO Date Oct 9, 2020
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Dr. Deborah A. Knobelman Ph.D.

Contact Details

Address:
1300 South El Camino Real
San Mateo, California
United States
Website https://kronosbio.com

Stock Details

Ticker Symbol KRON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001741830
CUSIP Number 50107A104
ISIN Number US50107A1043
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Deborah A. Knobelman Ph.D. Interim Chief Executive Officer, Chief Financial Officer, Chief Operating Officer & President
David M. Tanen J.D. Secretary & Director
Joshua A. Kazam Co-Founder & Director

Latest SEC Filings

Date Type Title
May 15, 2025 SC 14D9 Filing
May 15, 2025 SC TO-T Filing
May 08, 2025 10-Q Quarterly Report
May 01, 2025 SC14D9C Filing
May 01, 2025 8-K Current Report
Apr 25, 2025 10-K/A [Amend] Annual Report
Apr 10, 2025 8-K Current Report
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Dec 27, 2024 8-K Current Report